The use of an urticaria control test for the evaluation of omalizumab treatment response in patients diagnosed with chronic urticaria
Journal Title: Turkderm-Turkish Archives of Dermatology and Venereology - Year 2020, Vol 54, Issue 4
Abstract
Background and Design: Urticaria is a very common skin disease which is characterized by itchy, erythematous and edematous plaques. Angioedema can also be seen in half of the cases in addition to skin findings. In most cases of chronic urticaria, the underlying factor is not known. Omalizumab, a recombinant human monoclonal immunoglobulin G (IgG) antibody against IgE, is a safe treatment option in chronic urticaria cases which are resistant to treatment with antihistamines. This study aimed to evaluate the treatment responses of chronic urticaria patients taking omalizumab treatment with an urticaria control test (UCT). Materials and Methods: One hundred fifty-four patients diagnosed with chronic urticaria taking omalizumab treatment attended our evaluation between January 1, 2017 and December 31, 2018. These patients were evaluated with an UCT every four weeks. Sixty-six patients who were evaluated with an UCT during the course of the following 12 weeks were statistically analyzed. Thirty-nine of the patients received a treatment shorter than 12 months (the first group), and the remaining 27 patients received treatment for longer than 12 months (the second group). The patients were analyzed according to the duration of their treatment. Results: The first, second, and third average UCT scores of the 3 sequential applications for the first group were 9.16; 11.57; and 12.73; respectively. There was a statistically significant difference in the UCT scores between the 3 successive applications in the first group (p<0.05). On the other hand, the first, second, and third average UCT scores of the 3 sequential applications for the the second group were 11.20; 11.40; and 12.36 respectively. There was statistically significant difference in the UCT scores between the 3 successive applications for the second group. Conclusion: The effectiveness of omalizumab treatment in chronic urticaria patients with an UCT was investigated in this study. Omalizumab proved to be an effective treatment option in chronic urticaria patients.
Authors and Affiliations
Burhan Engin, Sera Nur Yücesoy, Özge Aşkın, Zekayi Kutlubay, Server Serdaroğlu
Keywords
Related Articles
- EP ID EP691625
- DOI 10.4274/turkderm.galenos.2020.06887
- Views 98
- Downloads 0
Evaluation of serum vitamin D levels in patients with lichen planus
Background and Design: Lichen planus (LP) is a chronic inflammatory disease of unknown etiology that most commonly affects the skin and oral mucosa. Vitamin D is a steroid hormone with immunomodulatory, anti-inflammatory...
Comparison of the plasma levels of cathepsin-L and granulysin between patients with psoriasis and healthy controls
Background and Design: Psoriasis is a chronic papulosquamous disease where histologically epidermal hyperproliferation and infiltration involving natural killer cells and cytotoxic T-cells are observed. These cells have...
The effectiveness of İstanbul Occupational Diseases Hospital on employer attitude and worker’s health in terms of occupational skin diseases
Background and Design: To examine the effectiveness of İstanbul Occupational Diseases Hospital on employer attitude and worker’s health in terms of occupational skin diseases and also to investigate the prognosis of occu...
Acute generalized exanthematous pustulosis induced by hydroxychloroquine associated with human leukocyte antigen-B51 (HLA-B51), DR1101,04, DQ03,05, and for the first time in the literature with HLA-B15
No summary
The frequency of epicardial fat pads detected by chest x-rays in psoriasis patients
Background and Design: Psoriasis is a chronic inflammatory skin condition associated with several systemic comorbidities including cardiovascular diseases (CVD). Epicardial fat pad (EFP) is defined as a visceral fat tiss...